Matrix Capital Management Company LP Has Upped Incyte Corp (INCY) Stake

Lloyd Doyle
April 16, 2018

The biopharmaceutical company reported $0.05 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.13 by $0.08. For the next financial year, analysts expect that the company will post sales of $2.05 billion per share, with estimates ranging from $1.82 billion to $2.28 billion. The company exchanged hands with 2205936 shares contrast to its average daily volume of 2.27M shares while its relative volume stands at 0.97. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Capital International Ltd. CA raised its stake in Incyte by 4.5% in the fourth quarter. The institutional investor held 13,017 shares of the commercial physical & biological resarch company at the end of 2017Q4, valued at $1.23 million, up from 9,196 at the end of the previous reported quarter.

In the trailing 12 months period, return on assets ratio of the Company was -15.80% and return on equity ratio was -23.30% while its return on investment ratio was -14.80%. The stock price closed last trading at $70.12. Burt Wealth Advsrs reported 2,188 shares.

Incyte Corporation (NASDAQ:INCY) closed at $70.12 a share in the latest session and the stock value rose nearly -25.96% since the beginning of this year. It has underperformed by 50.77% the S&P500. BMO Capital Markets restated a buy rating and set a $172.00 target price on shares of Incyte in a research note on Wednesday, January 3rd. Therefore 43% are positive.

Analysts suggested mean rating of 2.20, according to Finviz. (NYSE:V) earned "Buy" rating by Guggenheim on Monday, April 9. Piper Jaffray has "Hold" rating and $5200 target. The rating was maintained by UBS on Wednesday, November 4 with "Buy". $114's average target is 62.58% above currents $70.12 stock price. (NYSE:V) on Thursday, June 22 with "Buy" rating. Goldman Sachs Group Inc lifted their price objective on shares of Incyte from $116.00 to $149.00 and gave the company a buy rating in a report on Friday, January 27th. On Tuesday, August 18 the stock rating was maintained by Argus Research with "Buy". The firm earned "Sell" rating on Friday, July 21 by Berenberg. A simple moving average (SMA) is an mathematical moving average calculated by adding the closing price of the security for a number of time periods and then dividing this total by the number of time periods.


Since November 17, 2017, it had 0 insider purchases, and 1 insider sale for $292,234 activity. Griffin Asset Management Inc. acquired a new stake in Incyte in the fourth quarter valued at $200,000. It also increased its holding in Gilead Sciences Inc (NASDAQ:GILD) by 16,178 shares in the quarter, for a total of 239,715 shares, and has risen its stake in Schlumberger Ltd (NYSE:SLB). Its down 0.05, from 0.85 in 2017Q3. It improved, as 63 investors sold WFC shares while 746 reduced holdings. 59 funds opened positions while 153 raised stakes. Keybank Association Oh holds 3,536 shares. Davis Selected Advisers owns 26.24M shares. Employees Retirement System Of Texas has 7,000 shares for 0.01% of their portfolio. Shine Advisory Incorporated invested in 0.12% or 3,838 shares. The stock decreased 0.26% or $0.32 during the last trading session, reaching $120.75. Citigroup holds 0.01% or 128,632 shares. Wealthfront Inc reported 111,797 shares stake. Shamrock Asset Mngmt Lc invested in 2,878 shares. Maryland-based Invest Counselors Of Maryland Ltd Liability Company has invested 0.12% in Wells Fargo & Company (NYSE:WFC). Foster Dykema Cabot And Ma stated it has 6,042 shares or 0.1% of all its holdings. Synovus Financial Corp now owns 9,926 shares of the biopharmaceutical company's stock valued at $1,160,000 after purchasing an additional 593 shares during the last quarter. 26,546 are held by Loudon Mngmt Limited. The company has a debt-to-equity ratio of 0.01, a current ratio of 4.01 and a quick ratio of 3.99.

A number of other equities research analysts have also issued reports on the stock. Therefore 74% are positive. Incyte had 88 analyst reports since August 6, 2015 according to SRatingsIntel.

Gabelli downgraded shares of Incyte (NASDAQ:INCY) from a buy rating to a hold rating in a research report sent to investors on Monday, April 9th, MarketBeat reports. Blackrock invested 0.06% of its portfolio in Incyte Corporation (NASDAQ:INCY). Incyte Corporation (NASDAQ:INCY) has declined 39.22% since April 16, 2017 and is downtrending. The firm has "Buy" rating given on Friday, February 12 by Brean Capital.

Other reports by Iphone Fresh

Discuss This Article

FOLLOW OUR NEWSPAPER